Catalyst Collapses On FDA Firdapse Refusal
This article was originally published in Scrip
Executive Summary
Investors hit Catalyst Pharmaceuticals Inc. hard on Feb. 17, driving shares down 50%, after the company disclosed the FDA refused to file (RTF) the Florida firm's new drug application (NDA) for Firdapse (amifampridine phosphate), a 3,4-diaminopyridine phosphate, as a symptomatic treatment for two very rare neuromuscular diseases – Lambert Eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS).
You may also be interested in...
Catalyst Will Try To Salvage Rare Disease Drug from Failed Phase III Trial
Despite a Phase III study that found no statistically significant outcomes for its endpoints for Firdapse, Catalyst will seek FDA approval for treating a subgroup of patients who showed improvement
Phase III Data Support Catalyst's NDA Resubmission For Firdapse
Catalyst executives note that the company has completed everything the FDA requested to support resubmission of Firdapse for its first two rare disease indications – a second Phase III study in LEMS and abuse liability studies.
Seven Clinical Trial Read-Outs Due In Q4
The last three months of the year should see data reporting from a number of key studies for novel products including Roche's emicizumab. Scrip takes a look at some of the more interesting studies expected by year end, with the help of analysts from Informa's Biomedtracker.